Co-Diagnostics Inc (NASDAQ:CODX) saw unusually-strong trading volume on Thursday . Approximately 31,340,250 shares were traded during trading, an increase of 3,832% from the previous session’s volume of 797,125 shares.The stock last traded at $1.09 and had previously closed at $0.87.
Several equities analysts have commented on CODX shares. HC Wainwright reaffirmed a “buy” rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th. Maxim Group set a $25.00 price objective on Agilysys and gave the company a “buy” rating in a research report on Friday, May 17th. Finally, Zacks Investment Research raised Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research report on Monday.
The stock’s 50-day simple moving average is $0.82.
Co-Diagnostics (NASDAQ:CODX) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01). Co-Diagnostics had a negative net margin of 19,057.66% and a negative return on equity of 430.95%. Research analysts forecast that Co-Diagnostics Inc will post -0.09 EPS for the current year.
About Co-Diagnostics (NASDAQ:CODX)
Co-Diagnostics, Inc, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc was founded in 2013 and is headquartered in Salt Lake City, Utah.
See Also: What Does Beta Mean In Stock Selection
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.